ADmit Therapeutics
Marta Barrachina is a highly accomplished individual with a diverse background in research, academia, and business. Marta currently holds key positions in various organizations, such as being a Member of the Board of Directors and Co-Founder and CEO at ADmit Therapeutics. Marta's expertise extends to their roles as a Principal Investigator at IDIBELL and a Member of the Scientific Review Board at the Alzheimer's Drug Discovery Foundation, showcasing their commitment to advancing scientific knowledge and innovation. With a solid educational foundation including a Bsc. in Biochemistry, a PhD in Biochemistry and Immunology, and an MBA, Marta brings a wealth of knowledge and experience to their professional endeavors.
This person is not in any teams
ADmit Therapeutics
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer.